

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE OF CHIEF EXECUTIVE OFFICER

The Board announces that with effect from 27 May 2022:

- (i) Ms. Wu Guizhen has been appointed as an independent non-executive director of the Company;
- (ii) Mr. Cai Dongchen has ceased to be the Chief Executive Officer but remains as an executive director and Chairman of the Company; and
- (iii) Mr. Zhang Cuilong has been appointed as the Chief Executive Officer.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”) is pleased to announce that Ms. Wu Guizhen (“**Ms. Wu**”) has been appointed as an independent non-executive director of the Company with effect from 27 May 2022. The biographical details of Ms. Wu are set out below:

Ms. Wu, aged 62, is the Chief Expert of Biosafety of the Chinese Center for Disease Control and Prevention (“CDC”), the President of Asia-Pacific Biosafety Association and the key expert group leader of the National Key Research and Development Program “Biosafety Key Technology Research and Development” of the 13th and 14th Five-Year Plans. She is a “Young and Middle-Aged Expert with Outstanding Contributions” awarded by the Ministry of Health, a “March 8 Red Flag Bearer” and enjoys special government allowance from the State Council. She has served as the party committee’s secretary and legal representative of the National Institute for Viral Disease Control and Prevention of the CDC. Ms. Wu has long been engaged in the prevention and control of major infectious diseases, disposal of public health emergencies as well as biosafety management and research. She is the pioneer planner and founder of the laboratory biosafety management system in China and has strongly supported the swift response to major epidemics such as Covid-19 and Ebola, making significant contributions to the national security. Ms. Wu has presided over or participated in drafting and revising 15 biosafety regulations and standards in China, published, as editor-in-chief, 14 biosafety monographs including the Laboratory Biosafety Manual, and published, as corresponding author (including co-author), more than 70 articles in journals such as Nature, Science, Cell, The New England Journal of Medicine and Lancet. In January 2022, she was selected as one of the world’s top 100 thousand scientists (ranked 8171st in the world and 1st in the field of public health and preventive medicine in China). Ms. Wu is the founder and editor-in-chief of Biosafety and Health, the first English scientific journal of biosafety in China, and is also the editor-in-chief of Chinese Journal of Experimental and Clinical Virology and associate editor-in-chief of Chinese Journal of Virology. Ms. Wu received a bachelor’s degree in medicine from Beijing Medical College (now known as Peking University Health Science Center) and a postgraduate degree from China University of Political Science and Law. She was a senior visiting scholar at Harvard University.

Ms. Wu serves as the Deputy Director of the National Biosafety Expert Committee of the State Council, Deputy Director of the First to Third Biosafety Assessment Expert Committee of Pathogenic Microbiology Laboratory of the National Health Commission, member of the CAST UN Consultative Committee on Life Science and Human Health (CCLH), member of the Expert Committee of China National Center for Biotechnology Development, member of the Professional Committee of National Health Infectious Disease Standards, Chairwoman of the Public Health Committee of China Medical Women’s Association, Chairwoman of the Biological Resources and Management Branch of the Chinese Preventive Medicine Association, Deputy Director of the Biosafety and Protective Equipment Branch of the Chinese Prevention Medicine Association, member of the Biosafety Review Committee of the High-grade Pathogenic Microbiology Laboratory of the Ministry of Science and Technology, member of the Board of Appeals and the Biosafety Professional Committee of the China National Accreditation Service for Conformity Assessment.

Ms. Wu has entered into a service contract with the Company for a period of three years commencing from 27 May 2022 and she is subject to retirement by rotation and re-election at the general meeting in accordance with the Articles of Association of the Company. Ms. Wu is entitled to receive an annual director’s fee of HK\$200,000 which was recommended by the remuneration committee of the Company and determined by the Board with reference to her skills, experience and qualification as well as the prevailing market practices.

Ms. Wu has not held any other positions with any members of the Group and does not have any relationships with any directors, senior management or substantial or controlling shareholders of the Company. Save as disclosed above, Ms. Wu has not held any directorships in any listed public companies in the last three years. As at the date of this announcement, Ms. Wu does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Future Ordinance.

Save as disclosed above, there is no other information to be disclosed pursuant to rule 13.51(2) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) (“**Listing Rules**”) nor any other matters which need to be brought to the attention of the shareholders of the Company in connection with the appointment of Ms. Wu.

CHANGE OF CHIEF EXECUTIVE OFFICER

The Board of the Company announces the change of Chief Executive Officer with effect from 27 May 2022 as set out below:

- (1) Mr. Cai Dongchen (“**Mr. Cai**”) has ceased to act as the Chief Executive Officer of the Company (the “**CEO**”) in order to focus his time and effort more on the strategic level of the Company and facilitate the arrangement to separate the roles of Chairman and CEO so as to maintain a high standard of corporate governance. Mr. Cai remains as an executive director and Chairman of the Company.

Mr. Cai has confirmed that he has no disagreement with the Board and that he is not aware of any matters relating to his cessation as the CEO that need to be brought to the attention of Stock Exchange and the shareholders of the Company.

- (2) Mr. Zhang Cuilong (“**Mr. Zhang**”), an executive director, Vice-Chairman and Rotating CEO of the Company, has been appointed as CEO. The biographical details of Mr. Zhang are set out below:

Mr. Zhang, aged 53, was appointed as an executive director of the Company in 2018 and was appointed as Vice-Chairman and Rotating CEO on 21 May 2019. He is also a director of certain subsidiaries of the Company. Mr. Zhang holds a bachelor’s degree in pharmacology from Hebei Medical College (now known as Hebei Medical University) and has extensive technical, marketing and management experience in the pharmaceutical industry.

Mr. Zhang has entered into a service contract with the Company for a period of three years commencing from 9 July 2021 and he is subject to retirement and re-election at the general meeting in accordance with the articles of association of the Company. Mr. Zhang is entitled to receive a monthly salary of RMB57,750 and an annual director’s fee of HK\$63,000. He is also eligible to receive performance related discretionary bonus to be determined by the Board. His emoluments were recommended by the remuneration committee of the Company and determined by the Board with reference to his skills, experience and qualification as well as the prevailing market practices.

Save as disclosed above, Mr. Zhang has not held any other positions with any members of the Group and does not have any relationships with any directors, senior management or substantial or controlling shareholders of the Company. Save as disclosed above, Mr. Zhang has not held any directorships in any listed public companies in the last three years. As at the date of this announcement, Mr. Zhang does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Future Ordinance.

Save as disclosed above, there is no other information to be disclosed pursuant to rule 13.51(2) of the Listing Rules nor any other matters which need to be brought to the attention of the shareholders of the Company in connection with the appointment of Mr. Zhang.

The Board would like to take this opportunity to extend its warm welcome to Ms. Wu on joining the Board and Mr. Zhang on his new appointment, and express its sincere gratitude to Mr. Cai for his contribution during his tenure as the CEO and Mr. Zhang for his contribution during his tenure as the Rotating CEO.

By order of the board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 27 May 2022

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. WU Guizhen as independent non-executive directors.